PTCT insider exercises 55,000 options at $30.86 and sells same day
Rhea-AI Filing Summary
PTC Therapeutics insider Neil G. Almstead completed matched option exercises and open-market sales totaling 55,000 shares on 10/03/2025. The transactions were executed under a Rule 10b5-1 plan adopted on 12/10/2024, and consisted of two option exercises at an exercise price of $30.86 (total 55,000 shares acquired) and multiple sales at weighted-average prices ranging from $65.45 to $67.16. After these actions the reporting person directly holds 100,625 shares and the reporting persons spouse holds 6,179 shares indirectly; the report also notes 272 shares purchased through the employee stock purchase plan for the period ended 6/30/2025.
The filing shows the exercises funded sales executed the same day (net zero change from the matched option exercises and sales), and the reporting person certified the trades via an attorney-in-fact signature on 10/07/2025.
Positive
- Transactions executed under a Rule 10b5-1 plan adopted on 12/10/2024, indicating pre-planned execution
- Option exercises at $30.86 followed by sales, converting compensation into liquidity
- Reporting person retains substantial stake with 100,625 shares directly and 6,179 indirectly
Negative
- Significant same-day sales of 55,000 shares (total sold), which reduced immediately available exercised shares
- Multiple sale tranches at higher weighted-average prices indicate active disposals on 10/03/2025
Insights
Matched exercises and sales under a 10b5-1 plan show pre-planned liquidity, not ad-hoc disposition.
The report discloses that the transactions were effected pursuant to a written Rule 10b5-1 plan adopted on 12/10/2024, which provides an affirmative defense against insider trading claims when properly documented and executed. The reporting person exercised stock options at an exercise price of $30.86 and contemporaneously sold the resulting shares in multiple trades at weighted-average prices between $65.45 and $67.16, realizing immediate gross proceeds from the sales.
Key items to watch in the near term include any subsequent Form 4 filings that would show changes in holdings or additional 10b5-1 activity, and whether future exercises produce similar matched sales; these near-term items are monitorable through periodic SEC filings.
The filing shows option exercises converted to shares and sold the same day, leaving direct holdings at 100,625 shares.
The report lists two stock option exercises that together produced 55,000 shares exercisable and sold the same day, executed at an exercise price of $30.86. The individual retains 100,625 shares directly after the transactions, plus 6,179 indirectly via spouse; additionally, 272 shares came from the ESPP period ended 6/30/2025.
For compensation and dilution context, monitor future option grants, vesting schedules, and any disclosures of equity plan share pools in upcoming filings to assess potential dilution over the next 12 months.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 3,442 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 51,558 | $0.00 | -- |
| Exercise | Common Stock | 3,442 | $30.86 | $106K |
| Sale | Common Stock | 1,609 | $65.46 | $105K |
| Sale | Common Stock | 1,760 | $66.56 | $117K |
| Sale | Common Stock | 73 | $67.16 | $5K |
| Exercise | Common Stock | 51,558 | $30.86 | $1.59M |
| Sale | Common Stock | 23,419 | $65.45 | $1.53M |
| Sale | Common Stock | 23,863 | $66.45 | $1.59M |
| Sale | Common Stock | 4,276 | $67.15 | $287K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024 Includes 272 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2025. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.00 to $65.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.15 to $67.03 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.00 to $65.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.00 to $66.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $67.00 to $67.33 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Currently exercisable.
